CLEVELAND--(BUSINESS WIRE)--Arteriocyte, a clinical stage biotechnology company announced today that the company has been awarded $496,000 through the Global Cardiovascular Innovation Center (GCIC), to continue clinical research on its lead stem cell therapy (ACY001) for use in chronic coronary ischemia. This funding is in addition to the first year GCIC support received in 2007, to accelerate the company’s cardiac stem cell therapy development. Under the GCIC project, Arteriocyte participates as one of a number of companies working as research partners with the Cleveland Clinic.
